Molecular Biology of Choroidal Neovascularization

Ophthalmology Clinics of North America

Volumn 19, Issue 3, 2006, Pages 323-334

  Lu, Ming ^a   Adamis, Anthony P ^b  

^a Vantage Eye Center   (United States)

^b (OSI) Eyetech   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANECORTAVE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOSTATIN; BEVACIZUMAB; CURCUMIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; FUMAGILLOL CHLOROACETYLCARBAMATE; HYBRID PROTEIN; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; OCTREOTIDE; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; PLASMINOGEN; PLASMINOGEN KRINGLE 5; PROLACTIN; PROSTAGLANDIN SYNTHASE INHIBITOR; RANIBIZUMAB; RECOMBINANT ANTIBODY; THALIDOMIDE; THROMBOSPONDIN 2; TIE 1 RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN TRAP FUSION PROTEIN;

ANGIOMA; ANTIINFLAMMATORY ACTIVITY; CAPILLARY PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENDOPHTHALMITIS; HISTOPATHOLOGY; HUMAN; INJECTION SITE REACTION; IONTOPHORESIS; MOLECULAR BIOLOGY; NONHUMAN; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; BIOLOGICAL MARKERS; CHOROID; CHOROIDAL NEOVASCULARIZATION; DISEASE PROGRESSION; HUMANS; INJECTIONS; MOLECULAR BIOLOGY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 33748786807     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ohc.2006.05.001     Document Type: Review

References (142)

1. Ng E.W., and Adamis A.P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 40 (2005) 352-368
2. Campochiaro P.A., and Hackett S.F. Ocular neovascularization: a valuable model system. Oncogene 22 (2003) 6537-6548
3. Witmer A.N., Vrensen G.F., Van Noorden C.J., et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22 (2003) 1-29
4. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
5. Gragoudas E.S., Adamis A.P., Cunningham E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
6. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
7. Michels S., Rosenfeld P.J., Puliafito C.A., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 (2005) 1035-1047
8. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
9. The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122 (2004) 477-485
10. Edwards A.O., Ritter III R., Abel K.J., et al. Complement factor H polymorphism and age-related macular degeneration. Science 308 (2005) 421-424
11. Grossniklaus H.E., Martinez J.A., Brown V.B., et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 114 (1992) 464-472
12. Yannuzzi L.A., Negrao S., Iida T., et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 21 (2001) 416-434
13. Gass J.D.M. Stereoscopic atlas of macular diseases: diagnosis and treatment, vol. 2 (1997), CV Mosby, St. Louis
14. Green W.R. Histopathology of age-related macular degeneration. Mol Vis 5 (1999) 27
15. Ambati J., Ambati B.K., Yoo S.H., et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48 (2003) 257-293
16. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 109 (1991) 1109-1114
17. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. Arch Ophthalmol 112 (1994) 500-509
18. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol 112 (1994) 480-488
19. Freund K.B., Yannuzzi L.A., and Sorenson J.A. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol 115 (1993) 786-791
20. Treatment of Age Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 117 (1999) 1329-1345
21. Treatment of Age Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 119 (2001) 198-207
22. Bermig J., Tylla H., Jochmann C., et al. Angiographic findings in patients with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 240 (2002) 169-175
23. Hartnett M.E., Weiter J.J., Garsd A., et al. Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol 230 (1992) 11-19
24. Hartnett M.E., Weiter J.J., Staurenghi G., et al. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology 103 (1996) 2042-2053
25. Slakter J.S., Yannuzzi L.A., Schneider U., et al. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 107 (2000) 742-753
26. Rodriguez-Coleman H., Spaide R.F., and Yannuzzi L.A. Treatment of angiomatous lesions of the retina with photodynamic therapy. Retina 22 (2002) 228-232
27. Spaide R.F., Sorenson J., and Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 25 (2005) 685-690
28. Guttman C. Anti-VEGF AMD drug yields visual benefit. Available at: http://www.ophthalmologytimes.com/ophthalmologytimes/article/articleDeta il.jsp?id=175938. Accessed October 6, 2005.
29. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99 (2002) 11393-11398
30. Campochiaro P.A. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther 13 (2006) 559-562
31. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7 (2001) 575-583
32. Meyer M., Clauss M., Lepple-Wienhues A., et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18 (1999) 363-374
33. Senger D.R., Galli S.J., Dvorak A.M., et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
34. Ferrara N., Leung D.W., Cachianes G., et al. Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells. Methods Enzymol 198 (1991) 391-405
35. Burchardt M., Burchardt T., Chen M.W., et al. Expression of mRNA splice variants for VEGF in the penis of adult rats and humans. Biol Reprod 60 (1999) 398-404
36. Houck K.A., Leung D.W., Rowland A.M., et al. Dual regulation of vascular endothelial growth factor. J Biol Chem 267 (1992) 26031-26037
37. Ishida S., Usui T., Yamashiro K., et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198 (2003) 483-489
38. McColm J.R., Geisen P., and Hartnett M.E. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis 10 (2004) 512-520
39. Senger D., Connolly D., Van De Water L., et al. Purification and NH2-terminal amino acid sequence of guinea pig tumor secreted VPF. Cancer Res 50 (1990) 1774-1778
40. Plate K.H., Brier G., Weich H.A., et al. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845-848
41. Shweiki D., Itin A., Soffer D., et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845
42. Cao Y., Linden P., Shima D., et al. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 98 (1996) 2507-2511
43. Miller J.W., Adamis A.P., and Aiello L.P. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 13 (1997) 37-50
44. Millauer B., Wizigmann-Voos S., Schnurch H., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72 (1993) 835-846
45. De Vries C., Escobedo J.A., Ueno H., et al. The fms-like tyrosine kinase, a receptor for VEGF. Science 255 (1992) 989-991
46. Kukk E., Lymboussaki A., Taira S., et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122 (1996) 3829-3837
47. Carmeliet P., Ferreira V., Breir G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
48. Fong G.-H., Rossant J., Gertssenstein M., et al. Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376 (1995) 66-70
49. Shalaby F., Rossand J., Yamaguchi T.P., et al. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature 376 (1995) 62-66
50. Thieme H., Aiello L.P., Takagi H., et al. Comparitive analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 44 (1995) 98-103
51. Xia P., Aiello L.P., Ishii H., et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98 (1996) 2018-2026
52. Roberts W.G., and Palade G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108 (1995) 2369-2379
53. Lu M., Perez V.L., Ma N., et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci 40 (1999) 1808-1812
54. Miyamoto K., Khosrof S., Bursell S.E., et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 156 (2000) 1733-1739
55. Usui T., Ishida S., Yamashiro K., et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 45 (2004) 368-374
56. Sakurai E., Anand A., Ambati B.K., et al. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44 (2003) 3578-3585
57. Asahara T., Takahashi T., Masuda H., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18 (1999) 3964-3972
58. Csaky K.G., Baffi J.Z., Byrnes G.A., et al. Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. Exp Eye Res 78 (2004) 1107-1116
59. Aiello L.P., Pierce E.A., Foley E.D., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92 (1995) 10457-10461
60. Shima D.T., Deutsch U., and D'Amore P.A. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 370 (1995) 203-208
61. Papapetropoulos A., Garcia-Cardena G., Madri J.A., et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100 (1997) 3131-3139
62. Alon T., Hemo I., Itin A., et al. Vascular endothelial growth factor as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1 (1995) 1024-1028
63. Lamoreaux W.J., Fitzgerald M.E., Reiner A., et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 55 (1998) 29-42
64. Miller J., Adamis A.P., Shima D.T., et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145 (1994) 574-584
65. Tolentino M.J., Miller J.W., Gragoudas E.S., et al. Intravitreal injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103 (1996) 1820-1828
66. Tolentino M.J., Miller J.W., Gragoudas E.S., et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. Arch Ophthalmol 114 (1996) 964-970
67. Adamis A.P., Shima D.T., Tolentino M., et al. Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate. Arch Ophthalmol 114 (1996) 66-71
68. Ozaki H., Seo M.S., Ozaki K., et al. Blockade of VEGF receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 156 (2000) 697-707
69. Pe'er J., Shweiki D., Itin A., et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 72 (1995) 638-645
70. Adamis A.P., Miller J., Bernal M., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118 (1994) 445-450
71. Aiello L.P., Avery R.L., Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994) 1480-1487
72. Malecaze F., Clamens S., Simorre-Pinatel V., et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112 (1994) 1476-1482
73. Lutty G.A., McLeod S., Merges C., et al. Localization of VEGF in human retina and choroid. Arch Ophthalmol 114 (1996) 971-977
74. Spaide R.F. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 141 (2006) 149-156
75. Frank R.N., Amin R.H., Eliott D., et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 122 (1996) 393-403
76. Kvanta A., Algvere P.V., Berglin L., et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37 (1996) 1929-1934
77. Lopez P.F., Sippy B.D., Lambert H.M., et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37 (1996) 855-868
78. Wells J.A., Murthy R., Chibber R., et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 80 (1996) 363-366
79. Holekamp N.M., Bouck N., and Volpert O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 134 (2002) 220-227
80. Blaauwgeers H.G., Holtkamp G.M., Rutten H., et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation. Am J Pathol 155 (1999) 421-428
81. Holz F.G., Sheraidah G., Pauleikhoff D., et al. Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane. Arch Ophthalmol 112 (1994) 402-406
82. Kuroki M., Voest E.E., Amano S., et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98 (1996) 495-504
83. Lu M., Kuroki M., Amano S., et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101 (1998) 1219-1224
84. Baffi J., Byrnes G., Chan C.C., et al. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 41 (2000) 3582-3589
85. Schwesinger C., Yee C., Rohan R.M., et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 158 (2001) 1161-1172
86. Spilsbury K., Garrett K.L., Shen W.Y., et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 157 (2000) 135-144
87. Amin R., Puklin J.E., and Frank R.N. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 35 (1994) 3178-3188
88. Ogata N., Nishikawa M., Nishimura T., et al. Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Am J Ophthalmol 133 (2002) 851-852
89. Yi X., Ogata N., Komada M., et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol 235 (1997) 313-319
90. Soubrane G., Cohen S.Y., Delayre T., et al. Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig. Curr Eye Res 13 (1994) 183-195
91. Kimura H., Sakamoto T., Hinton D.R., et al. A new model of subretinal neovascularization in the rabbit. Invest Ophthalmol Vis Sci 36 (1995) 2110-2119
92. Tobe T., Ortega S., Luna J.D., et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153 (1998) 1641-1646
93. Yamada H., Yamada E., Kwak N., et al. Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina. J Cell Physiol 185 (2000) 135-142
94. Bouck N. PEDF anti-angiogenic guardian of ocular function. Trends Mol Med 8 (2002) 330-334
95. Dawson D.W., Volpert O.V., Gillis P., et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285 (1999) 245-248
96. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59 (1994) 471-482
97. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
98. Duh E.J., Yang H.S., Suzuma I., et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 43 (2002) 821-829
99. Mori K., Gehlbach P., Ando A., et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 43 (2002) 2428-2434
100. Ohno-Matsui K., Morita I., Tombran-Tink J., et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 189 (2001) 323-333
101. Renno R.Z., Youssri A.I., Michaud N., et al. Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 43 (2002) 1574-1580
102. Mori K., Gehlbach P., Yamamoto S., et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 43 (2002) 1994-2000
103. Campochiaro P.A., Dong N.Q., Mahmood S.S., et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 17 2 (2006) 177-179
104. Martin G., Schlunck G., Hansen L.L., et al. Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol 242 (2004) 321-326
105. Duh E.J., Yang H.S., Haller J.A., et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol 137 (2004) 668-674
106. Yancopoulos G.D., Davis S., Gale N.W., et al. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
107. Thurston G., Rudge J.S., Ioffe E., et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6 (2000) 460-463
108. Oh H., Takagi H., Suzuma K., et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 274 (1999) 15732-15739
109. Takagi H., Koyama S., Seike H., et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 44 (2003) 393-402
110. Thurston G., Suri C., Smith K., et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286 (1999) 2511-2514
111. Otani A., Takagi H., Oh H., et al. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci 40 (1999) 1912-1920
112. Hangai M., Moon Y.S., Kitaya N., et al. Systemically expressed soluble tie2 inhibits intraocular neovascularization. Hum Gene Ther 12 (2001) 1311-1321
113. Hangai M., Murata T., Miyawaki N., et al. Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 42 (2001) 1617-1625
114. Kim I., Moon S.O., Park S.K., et al. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 89 (2001) 477-479
115. Hammes H.P., Brownlee M., Jonczyk A., et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 2 (1996) 529-533
116. Luna J., Tobe T., Mousa S.A., et al. Antagonists of integrin alpha-v beta-3 inhibit retinal neovascularization in a murine model. Lab Invest 75 (1996) 563-573
117. Kamizuru H., Kimura H., Yasukawa T., et al. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci 42 (2001) 2664-2672
118. Takahashi T., Nakamura T., Hayashi A., et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. Am J Ophthalmol 130 (2000) 774-781
119. Krzystolik M.G., Afshari M.A., Adamis A.P., et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120 (2002) 338-346
120. Honda M., Sakamoto T., Ishibashi T., et al. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther 7 (2000) 978-985
121. Adamis A.P., Altaweel M., Bressler N.M., et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113 (2006) 23-28
122. Mordenti J., Cuthbertson R.A., Ferrara N., et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27 (1999) 536-544
123. Renno R.Z., Terada Y., Haddadin M.J., et al. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol 122 (2004) 1002-1011
124. Genentech, Inc. Phase 3 study shows Lucentis improved vision in patients with wet age-related macular degeneration (2005), Soth, San Francisco
125. Saishin Y., Saishin Y., Takahashi K., et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195 (2003) 241-248
126. Penn J.S., Rajaratnam V.S., Collier R.J., et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 42 (2001) 283-290
127. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 110 (2003) 2372-2383
128. Slakter J.S., Bochow T.W., D'Amico D.J., et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 113 (2006) 3-13
129. Schmidt-Erfurth U., Michels S., Michels R., et al. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol 15 (2005) 482-485
130. Gao G., Li Y., Gee S., et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 277 (2002) 9492-9497
131. Danis R.P., Bingaman D.P., Yang Y., et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 103 (1996) 2099-2104
132. Jonas J.B., Kreissig I., Sofker A., et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121 (2003) 57-61
133. Martidis A., Duker J.S., Greenberg P.B., et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109 (2002) 920-927
134. Sennlaub F., Valamanesh F., Vazquez-Tello A., et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 108 (2003) 198-204
135. Sakamoto T., Soriano D., Nassaralla J., et al. Effect of intravitreal administration of indomethacin on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 113 (1995) 222-226
136. Mousa S.A. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr Opin Chem Biol 6 (2002) 534-541
137. Lu M., and Adamis A.P. Ocular delivery of angiostatic agents. Int Ophthalmol Clin 44 (2004) 41-51
138. McLeod D.S., Taomoto M., Cao J., et al. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 43 (2002) 474-482
139. Ambati J., and Adamis A.P. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res 21 (2002) 145-151
140. Carrasquillo K.G., Ricker J.A., Rigas I.K., et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci 44 (2003) 290-299
141. Kim I., Ryan A.M., Rohan R., et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 40 (1999) 2115-2121 [erratum in Invest Ophthalmol Vis Sci 2000;41:368]
142. Oosthuyse B., Moons L., Storkebaum E., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28 (2001) 131-138